Last updated: March 7, 2024
Sponsor: Region Skane
Overall Status: Active - Recruiting
Phase
1
Condition
Myopic Macular Degeneration
Retina
Treatment
Dexamethasone Ophthalmic
Clinical Study ID
NCT05387941
2022-00536-01
2020-004933-19
Ages < 30 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Infants screened for retinopathy of prematurity (ROP) at Sahlgrenska UniversityHospital in Gothenburg, at Skåne University Hospital in Malmö and Lund and atHelsingborg Hospital.
- zone I stage 1 or 2 ROP without plus disease, posterior zone II stage 2 ROP withoutplus disease, or zone II stage 3 ROP without plus disease. ROP needs to be documentedby digital widefield photography and classification confirmed by two ophthalmologist.
Exclusion
Exclusion Criteria:
- ocular infection
- systemic steroid treatment within two weeks before the start of drop treatment
Study Design
Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Dexamethasone Ophthalmic
Phase: 1
Study Start date:
June 14, 2022
Estimated Completion Date:
December 31, 2028
Connect with a study center
Skåne University Hospital
Lund, Skåne 22185
SwedenActive - Recruiting
Sahlgrenska University Hospital
Göteborg, Västra Götaland 41685
SwedenActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.